<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
31.07.2019 17:09:00

Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings?

The period from May through late July tends to be unexciting for biotech stocks, in part because for various logistical reasons, first-quarter earnings are usually ho-hum across the industry. Second-quarter earnings, though, are often much stronger, which provides a spark for share prices. With that in mind, let's consider Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD), both of which released their Q2 results after the closing bell Tuesday. Are either of these biotech heavyweights more compelling buys in the wake of their earnings reports?Image Source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

(Anzeige)Passende emittierte Barrier Reverse Convertibles

Basiswert Valor Fälligkeitstag Maximale Rendite p.a.
Gilead Sciences Inc. / Johnson & Johnson / Pfizer Inc. 39255387 05.08.2020 8.68 %

Nachrichten zu Amgen Inc Cert.Deposito Arg.Repr. 0.2 Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Amgen Inc Cert.Deposito Arg.Repr. 0.2 Shsmehr Analysen

Eintrag hinzufügen

Energiemarkt-Update: Quo vadis Rohölpreis? | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News

pagehit